Last reviewed · How we verify
Fibrin Pad
Fibrin Pad is a hemostatic agent that forms a fibrin clot matrix to promote rapid hemostasis and wound sealing at surgical sites.
Fibrin Pad is a hemostatic agent that forms a fibrin clot matrix to promote rapid hemostasis and wound sealing at surgical sites. Used for Hemostasis during surgical procedures, Control of bleeding in general, cardiac, and vascular surgery.
At a glance
| Generic name | Fibrin Pad |
|---|---|
| Sponsor | Ethicon, Inc. |
| Drug class | Hemostatic agent |
| Modality | Small molecule |
| Therapeutic area | Surgery/Hemostasis |
| Phase | Phase 3 |
Mechanism of action
The pad consists of fibrinogen and thrombin that polymerize upon contact to create a stable fibrin clot, which adheres to bleeding surfaces and provides mechanical hemostasis. This allows for rapid control of bleeding during surgical procedures without requiring sutures or additional hemostatic measures. The fibrin matrix is gradually absorbed by the body as wound healing progresses.
Approved indications
- Hemostasis during surgical procedures
- Control of bleeding in general, cardiac, and vascular surgery
Common side effects
- Infection at surgical site
- Seroma formation
- Allergic reaction
Key clinical trials
- Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects (NA)
- Efficacy of Buccal Pad of Fat, Advanced Platelet Rich Fibrin, Fibrin Glue and Oxidized Cellulose Plug in Management of Oro-Antral Communication, Comparative Clinical Study (NA)
- Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis (PHASE3)
- Effect of Buccal Fat Pad and Platelet Rich Fibrin After Ultrasonic Hydrodynamic Maxillary Sinus Membrane Elevation (PHASE4)
- The Fibrin Pad Cardiovascular Study (PHASE2)
- The Fibrin Pad CV Phase III Study (PHASE3)
- Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery (PHASE3)
- Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrin Pad CI brief — competitive landscape report
- Fibrin Pad updates RSS · CI watch RSS
- Ethicon, Inc. portfolio CI